Review papers with raw data transparency

Visual paper analysis — "Biomarkers of inflammation in respiratory tract infections: a narrative review" (DOI: 10.18054/pb.v127i1-2.35792)

Interpretive text (concise, evidence-linked)

• Scope & methods: The paper is a narrative PubMed review (2005–2025) that screened 451 hits and included 73 full-text articles for synthesis; it describes CRP and PCT as the backbone biomarkers and summarizes newer candidates (calprotectin, PTX3, presepsin) and combination POCT panels (Saracevic et al., narrative review).
• Accurate strengths:
  • Clear summary of biological rationale and kinetics for each biomarker (e.g., CRP driven by IL-6; PCT rises within hours) and clinical contexts (primary care POCT for CRP) (Saracevic et al., methods & results).
  • Inclusion of POCT combination approaches (TRAIL/IP-10/CRP, MxA/CRP) and caution about heterogeneous study quality — a correct and clinically important point (Saracevic et al., POCT combinations).
• Major limitations (paper-level, evidence-based critique):
  1. As a narrative review it lacks explicit risk-of-bias assessment, formal grading (e.g., GRADE) or quantitative meta-analysis; that reduces reproducibility and limits readers' ability to assess aggregate effect sizes and heterogeneity (Saracevic et al., methods limitations).
  2. Thresholds and assay-platform variability are discussed but not systematically tabulated with assay-specific performance metrics; thresholds (e.g., CRP 20/30/50 mg/L; PCT 0.1–0.8 µg/L) are context-dependent and require metanalytic treatment for robust guidance (Saracevic et al., thresholds).
  3. Selection bias risk: restricting to PubMed and English-language, and not providing the PRISMA checklist or the included study table with key metadata (design, n, age groups, assay used) limits transparency despite showing a flow diagram; the PRISMA figure is referenced but underlying study list with extraction matrix is missing (Saracevic et al., transparency gap).
• Clinical/practical context & evidence alignment:
  • Procalcitonin-guided antibiotic algorithms are supported by randomized trials and Cochrane-level evidence for reducing antibiotic exposure and improving outcomes in selected settings; the review cites this literature but could strengthen recommendations by referencing pooled RCT effects (Cochrane PCT-guided therapy review).
  • CRP POCT in primary care reduces antibiotic prescribing (Cochrane and guideline data) — the review mentions this and the practical point that CRP is the only widely used bedside test in primary care (Cochrane CRP POCT review).
• Emerging biomarkers (what the review gets right and where it falls short):
  • Calprotectin: the review correctly highlights calprotectin as a neutrophil-derived early marker with promise across sputum/BAL/serum and a potential role in COVID-19 severity prediction; it cites prospective multicenter COVID-19 work but does not systematically present effect sizes or assay cutoffs (Saracevic et al., calprotectin summary).
  • PTX3 & Presepsin: review appropriately notes earlier peak kinetics and local production for PTX3 and rapid rise of presepsin, and their prognostic potential; however, it omits an assessment of analytical availability, inter-assay CVs, and confounding (renal dysfunction affects presepsin), which are clinically important (Saracevic et al., PTX3 and presepsin).
• Biases, blindspots & potential errors:
  • The review lists heterogeneity and potential publication bias among included studies, but does not quantify small-study effects or industry sponsorship among the trials cited (notably PCT literature has had industry ties in several trials and assays) — this is a recurring source of bias in biomarker literature (Cochrane PCT review sponsorship note).
  • Clinical heterogeneity (primary care vs ICU vs pediatrics) changes pre-test probability and threshold utility; the review sometimes mixes contexts without always clarifying where thresholds apply (e.g., CRP 30 mg/L in primary care vs CRP >100 mg/L associated with worse outcomes in inpatients) (Saracevic et al., thresholds context).
• Actionable takeaways for researchers & clinicians:
  1. Use CRP POCT in primary care to reduce unnecessary antibiotics — but pair with communication strategies and local guidelines; interpret thresholds contextually (CRP POCT guidance).
  2. PCT is useful within algorithmic strategies (initiate/discontinue antibiotics) supported by RCT evidence; caution in renal dysfunction and certain localized infections (Procalcitonin RCT evidence).
  3. New biomarkers (calprotectin, PTX3, presepsin) are promising for early detection/prognosis but require standardized assays, multi-center validation cohorts, and cost-effectiveness analyses before routine use (Saracevic et al., recommendations).

Where this review would be improved (concrete upgrades)

1. Provide a study extraction table (per-study n, setting, assay, cutoff, sensitivity/specificity, RoB) and an online supplement for reproducibility.
2. Use formal RoB tools and GRADE to transparently present evidence strength per biomarker.
3. When possible, run pooled diagnostic meta-analyses by setting (primary care, inpatient, ICU) for the most-studied markers (CRP, PCT) and present heterogeneity and threshold effects.